Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TIV + LAIV
- Development stage
- Unknown
- Lead developer
- MedImmune
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal, Intramuscular
01
Overview
TIV + LAIV refers to a vaccination regimen involving the sequential or comparative administration of the Trivalent Inactivated Influenza Vaccine (TIV) and the Live Attenuated Influenza Vaccine (LAIV). This specific combination was the subject of a Phase 4 clinical trial (NCT01184690) sponsored by the University of Rochester to evaluate the safety, viral shedding, and immunogenicity in healthy children aged 2 to 9 years. The TIV component is an inactivated vaccine typically administered via intramuscular injection, while the LAIV component (such as FluMist) contains live-attenuated viruses administered intranasally. The vaccines used in the Rochester study targeted three influenza strains: A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), which were the recommended components for the 2010–2011 Northern Hemisphere influenza season.
- Brand names
- FluMist
- Other names
- Trivalent Influenza Vaccine and Live Attenuated Influenza VaccineLAIV and TIV Influenza Vaccines in Children
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on TIV + LAIV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TIV + LAIV.